AEON Biopharma, Inc. (AEON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AEON Biopharma, Inc. (AEON) has a cash flow conversion efficiency ratio of 0.131x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.60 Million) by net assets ($-19.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is AEON Biopharma, Inc.'s balance sheet to measure how much of total assets are equity-financed.
AEON Biopharma, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how AEON Biopharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AEON Biopharma, Inc. (AEON) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
AEON Biopharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AEON Biopharma, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VerifyMe Inc
NASDAQ:VRME
|
0.005x |
|
BLB Limited
NSE:BLBLIMITED
|
-0.024x |
|
Zacatecas Silver Corp
V:ZAC
|
-0.018x |
|
AVA Risk Group Ltd
AU:AVA
|
0.140x |
|
AIRIQ INC.
F:EPXN
|
0.026x |
|
Digitree Group S.A
WAR:DTR
|
0.140x |
|
Wescan Goldfields Inc
V:WGF
|
1.871x |
|
NextPoint Capital SOCIMI S.A.
MC:YNPC
|
N/A |
Annual Cash Flow Conversion Efficiency for AEON Biopharma, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of AEON Biopharma, Inc. from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see AEON Biopharma, Inc. (AEON) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-28.57 Million | $-20.29 Million | 0.710x | +127.30% |
| 2023-12-31 | $-153.04 Million | $-47.83 Million | 0.312x | +137.47% |
| 2022-12-31 | $-270.41 Million | $-35.58 Million | 0.132x | +3.59% |
| 2021-12-31 | $-223.82 Million | $-28.43 Million | 0.127x | +172.88% |
| 2020-12-31 | $-203.23 Million | $-9.46 Million | 0.047x | -93.14% |
| 2019-12-31 | $-65.87 Million | $-44.73 Million | 0.679x | -- |
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of ga… Read more